Skip to main content

Profile: Dhara Surati

Dhara Shah
Dhara Surati, Pharm.D., BCPS
Clinical Associate Professor
Director of Pharmaceutical Care Teaching Laboratories

Health 2
University of Houston College of Pharmacy
4849 Calhoun, Room 4014
Houston, TX 77204-5039

832-842-8346
dnshah@central.uh.edu

Education and Post-graduate Training

Doctor of Pharmacy, Summa Cum Laude, University of Houston College of Pharmacy, Houston, Texas

Clinical Research Curriculum, University of Texas Medical School, Houston, Texas, 2009 - present

15th Annual Fellows Course in Hospital Epidemiology and Infection Control, July 6–8, 2011, Johns Hopkins University, Baltimore, Maryland

Infectious Diseases Fellow, University of Houston-College of Pharmacy, Houston, Texas, Mentors: Kevin W. Garey, Pharm.D., M.S., and Herbert L. DuPont, M.D.

PGY-1 Pharmacy Practice Resident, Memorial Hermann-Texas Medical Center, Houston, Texas, Program Director: Bradley Domonoske, Pharm.D., BCPS

Research Interests

Patient-oriented clinical and translational research in the areas of healthcare associated infections and enteric diseases, including:

  • Antibiotic-associated diarrhea
  • Clostridium difficile infection
  • Candida infections

Selected Peer-Reviewed Publications

Reveles KR, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, Alam MJ, Garey KW. Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 May 17;68(11):1887-1893. doi: 10.1093/cid/ciy782. 

Dotson KM, Aitken SL, Sofjan AK, Shah DN, Aparasu RR, Garey KW. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 Jul;146(9):1101-1105. doi: 10.1017/S0950268818001036. Epub 2018 May 9. PMID: 29739486

Sofjan AK, Mitchell A, Shah DN, Nguyen T, Sim M, Trojcak A, Beyda ND, Garey KW. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 Sep;14:58-64. doi: 10.1016/j.jgar.2018.02.013. Epub 2018 Feb 24. PMID: 29486356

Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, Barbut F, Shah DN, DuPont HL. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 Sep;50(8):631-7. doi: 10.1097/MCG.0000000000000473. PMID: 26796081

Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus. 2016 Aug 2;5(1):1224. doi: 10.1186/s40064-016-2825-x. eCollection 2016. PMID: 27536508 

Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20. PMID: 27209056

Kilic A, Alam MJ, Tisdel NL, Shah DN, Yapar M, Lasco TM, Garey KW. Multiplex real-time PCR method for simultaneous identification and toxigenic type characterization of Clostridium difficile from stool samples. Ann Lab Med. 2015 May; 35(3):306-13.

Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, Hu M, Shah DN, Shields K, Leffler DA, Kelly CP. A multi-center prospective and validation of a clinical prediction tool for severe Clostridium difficile infection. PLoS One. 2015 April; 10(4): eCollection 2015.

Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014 Jul 24; 9(7):e102848.

Aitken SL, Beyda ND, Shah DN, Palmer HR, Lasco TM, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: Role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun;48(6):683-90. doi: 10.1177/1060028014529928. Epub 2014 Mar 31. PMID: 24687545

Bower DR, Hunter AS, Jacobs DM, Kuper KM, Musick WL, Perez KK, Shah DN, Schilling AN. Significant publications on infectious diseases pharmacotherapy in 2012. Am J Health Syst Pharm. 2013; 70(21):1930-40.

Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, Garey KW. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep;85(1):28-32. doi: 10.1016/j.jhin.2013.04.017. Epub 2013 Jul 5. PMID: 23834988

Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr;83(4):294-9. doi: 10.1016/j.jhin.2012.12.011. Epub 2013 Feb 20.

Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb;68(2):438-43. doi: 10.1093/jac/dks388. Epub 2012 Oct 19. Review.

Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW.  A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: Implications for antibiotic stewardship programs. Pharmacother. 2012;32(2):129-134.

Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose optimization protocol: A potential policy for antibiotic stewardship programs. Am J Health Syst Pharm. 2012 Jun 1;69(11):979-84.

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun;56(6):3239-43.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011; 66(9):2146-51.

Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, DuPont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011; 66(12):2850-5.

Halton K, Arora V, Singh V, Ghantoji SS, Shah DN, Garey KW. Bacterial Colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. Clin Microbiol Infect. 2011; 17(6):868-9.

Hirsch EB, Cottreau JM, Ikwuagwu JO, Lusardi K, Mohr JF, Rodriguez SM, Shah DN, Tran TT. Significant publications on infectious diseases pharmacotherapy in 2010. Am J Health Syst Pharm. 2011; 68(21):2075-85.

Shah D, Dang MDQ, Hasbun R, Koo HL, Jiang ZD, DuPont HL, and Garey KW. Clostridium difficile infection - An update on emerging antibiotic treatment options and antibiotic resistance. Exp Rev Anti-infect Ther. 2010; 8(5):555-64.

Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Annals of Pharmacotherapy. 2008; 42(6):827-35.

Hendley R, Laegeler A, Clowe J, Shah D, Shields R, Stewart B. Preliminary 2006 comparison of Medicare Part D prescription drug plans. TSHP Journal. 2006; 7(2):6-11. 

Abstracts and Presentations

Shah DN, Aitken SL, Barragan LF, Goddu S, Navarro ME, DuPont HL, Garey KW. Economic burden of Clostridium difficile infection in hospitalized patients. 54th ICAAC, Washington, DC. September 5-9, 2014

Shah DN, Esquer Z, Ruelas DJ, DuPont HL, Garey KW. Outcome of Patients with Clostridium difficile Infection in a Large Tertiary Care Hospital in Houston. 53rd ICAAC, Denver, CO. September 10-13, 2013.

Shah, DN, Laine ME, Wei W, Smith LC, Palmer HR, Musick WL, Garey KW. Treatment Patterns in Hospitalized Patients with Multiple Clostridium difficile Infection Recurrences and Assessment of Ongoing Use of Pharmacologic Risk Factors. 53rd ICAAC, Denver, CO. September 10-13, 2013.

Grimes CZ, Shah DN, Koo HL, DuPont HL. Validity of recommended criteria for attributable mortality associated with Clostridium difficile Infection. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Garey KW, Shah DN, Habib M, Lasco T. Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Shah DN, Koo HL, Lasco TM, Palmer HR, Garey KW. Assessment of attributable mortality rate of candidemia in candidemia pts with inpatient mortality. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Dima-ala A, Dolormente K, Arora V, Garey KW. Incidence of antibiotic-associated diarrhea in hospitalized patients given broad spectrum antibiotics. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Yau R, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Pre-exposure to antifungals as a risk factor for fluconazole-non-susceptible Candida species in hospitalised patients with candidemia. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Santimaleeworagun W, Christensen J, Singh V, Shah DN, Chang KT ,Tam VH, Garey KW Molecular epidemiology of Clostridium difficile and prevalence of the NAP-1strain among patients admitted to a general and a private hospital in Houston, Texas USA. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Garey KW, Ghantoji S, Shah D, Habib M, Arora V, Jiang ZD, DuPont H. A randomised, double-blind, placebo-controlled pilot study to assess the effect of rifaximin “chaser” to prevent recurrent diarrhoea in patients with Clostridium difficile infection. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Xu R, Salazar M, Weston JS, Shah DN, Putney KS, Garey KW. Susceptibility of Candida species in patients with candidemia. SCCM’s 40th Critical Care Congress, San Diego, CA. January 16-18, 2011.

De La Cabada J, Jiang Z-D, Ghantoji SS, Garey KW, Lasco TM, Larocco M, Shah D, DuPont HL. Fecal lactoferrin in Clostridium difficile infection as a predictor of single bouts vs. recurrent disease. IDSA 48th Annual Meeting, Vancouver, Canada. October 21-24, 2010 (ORAL).

Shah DN, Yau RW, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Utility of fluconazole as de-escalation therapy in patients with fluconazole-susceptible candidemia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010 (ORAL).

Gordon SM, Shah DN, Tran TC, Lasco T, Garey KW. Variations in time to blood culture positivity stratified by Candida species and fluconazole susceptibility. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Daptomycin dose-effect relationship against vancomycin-resistant enterococcal bacteremia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Shah DN, Yau RW, Weston J, Xu R, Salazar M, Palmer H, Garey KW. Changes to empiric antifungal therapy based on susceptibility testing results. 50th ICAAC, Boston, MA. Sept. 12-15, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Evaluation of daptomycin PK/PD dose optimization protocol. 50th ICAAC, Boston, MA. Sept. 12-15, 2010 (ORAL).

Xu R, Weston JS, Salazar M, Shah DN, Garey KW. Susceptibility and recurrence of Candida species before and after a formulary change from caspofungin to micafungin in patients with candidemia. 44th ASHP Midyear Meeting, Las Vegas, NV. Dec. 5-10.

Awards and Honors

  • Faculty Preceptor Award, University of Houston College of Pharmacy, 2016
  • ICAAC Infectious Diseases Fellows Grant, American Society of Microbiology, 2010, 2011
  • Best Resident/Fellow Poster Winner, American College of Clinical Pharmacy, 2010
  • Special Recognition Award: Excellence in Clinical Skills, University of Houston College of Pharmacy, 2008
  • Golden Key International Honor Society, University of Houston, 2007
  • Rho Chi Pharmaceutical Honor Society, University of Houston College of Pharmacy, 2006
  • Sandra Evans Webb Scholarship, TSHP R&E Foundation, 2007 – 2008

Memberships

  • Infectious Diseases Society of America, 2011 – present
  • American College of Clinical Pharmacy, 2010 – present
  • The Society of Infectious Disease Pharmacists, 2010 – present
  • American Society for Microbiology, 2009 – present

CV